Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2020 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019; Coronavirus Aid, Relief, and Economic Security (CARES) Act and provisions regarding net operating loss (NOL); H.R. 6238, "Cameron's Law to reinstate full Orphan Drug Tax Credit for clinical testing expenses for rare diseases or conditions; provisions in COVID-19 relief legislation relating to net operating loss; H.R. 133, Consolidated Appropriations Act of 2021.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues; HR 133, Consolidated Appropriations Act of 2021
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues; H.R. 6900, HEROES Act tax issues; HR 133, Consolidated Appropriations Act of 2021
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019; Coronavirus Aid, Relief, and Economic Security (CARES) Act and provisions regarding net operating loss (NOL); H.R. 6238, "Cameron's Law to reinstate full Orphan Drug Tax Credit for clinical testing expenses for rare diseases or conditions; provisions in COVID-19 relief legislation relating to net operating loss.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues; H.R. 6900, HEROES Act tax issues
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019; Coronavirus Aid, Relief, and Economic Security (CARES) Act and provisions regarding net operating loss (NOL); H.R. 6238, "Cameron's Law to reinstate full Orphan Drug Tax Credit for clinical testing expenses for rare diseases or conditions.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Taxation/Internal Revenue Code
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE